52756-36-2Relevant articles and documents
Discovery of orally efficacious RORγt inverse agonists, part 1: Identification of novel phenylglycinamides as lead scaffolds
Shirai, Junya,Tomata, Yoshihide,Kono, Mitsunori,Ochida, Atsuko,Fukase, Yoshiyuki,Sato, Ayumu,Masada, Shinichi,Kawamoto, Tetsuji,Yonemori, Kazuko,Koyama, Ryoukichi,Nakagawa, Hideyuki,Nakayama, Masaharu,Uga, Keiko,Shibata, Akira,Koga, Keiko,Okui, Toshitake,Shirasaki, Mikio,Skene, Robert,Sang, BiChing,Hoffman, Isaac,Lane, Wes,Fujitani, Yasushi,Yamasaki, Masashi,Yamamoto, Satoshi
, p. 483 - 500 (2018)
A series of novel phenylglycinamides as retinoic acid receptor-related orphan receptor-gamma t (RORγt) inverse agonists were discovered through optimization of a high-throughput screen hit 1. (R)-N-(2-((3,5-Difluoro-4-(trimethylsilyl)phenyl) amino)-1-(4-m
AZA-ARYL 1H-PYRAZOL-1-YL BENZENE SULFONAMIDES
-
, (2018/02/28)
Compounds are provided that act as potent antagonists of the CCR(9) receptor for treating Sjogren's syndrome. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions.
Heterocyclic compound
-
, (2016/10/08)
The present invention relates to compound (I) or a salt thereof which has a ROR γ t inhibitory action. wherein each symbol is as defined in the specification.